Methods of high throughput biophysical characterization in biopharmaceutical development

Current Drug Discovery Technologies

Volumn 10, Issue 1, 2013, Pages 59-70

  Razinkov, Vladimir I ^a   Treuheit, Michael J ^a   Becker, Gerald W ^a  

^a AMGEN INC   (United States)

Author keywords

Biopharmaceuticals; Biophysical characterization; Design of experiment; Drug development; High throughput method; Manufacturability; Mass spectrometry; Protein characterization

Indexed keywords

ABSORPTION; CALORIMETRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; ELECTROSPRAY; FLUORESCENCE; GEL PERMEATION CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; ISOTHERMAL TITRATION CALORIMETRY; LIGHT SCATTERING; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLARIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; REVIEW; SPECTROSCOPY; SURFACE PLASMON RESONANCE; TURBIDITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VISCOSITY;

EID: 84875421347     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163811310010008     Document Type: Review

References (101)

1. Bergese P, Cretich M, Oldani C, et al. Advances in parallel screening of drug candidates. Curr Med Chem 2008; 15: 1706-19.
2. Rodrigues AD, Lin JH. Screening of drug candidates for their drug-drug interaction potential. Curr Opin Chem Biol 2001; 5: 396-401.
3. Sidhu SS. Phage display in pharmaceutical biotechnology. Curr Opin Biotech 2000; 11: 610-6.
4. Bratkovic T. Progress in phage display: evolution of the technique and its application. Cell Mo. Life Sci 2010; 67: 749-67.
5. Higgins LM, Lambkin I, Donnelly G, et al. In vivo phage display to identify M cell-targeting ligands, J Pharm Res 2004; 21: 695-705.
6. Pierce MM, Raman CS, Nall BT. Isothermal titration calorimetry of protein-protein interactions. Methods 1999; 19: 213.
7. Peters WB, Frasca V, Brown RK. Recent developments in isothermal titration calorimetry label free screening. Comb Chem High Throughput Screen 2009; 12: 772-90.
8. Torres FE, Recht MI, Coyle JE, Bruce RH, Williams G. Higher throughput calorimetry: opportunities, approaches and challenges. Curr Opin Struct Biol 2010; 20: 598-605.
9. Rich RL, Myszka DG. Advances in surface plasmon resonance biosensor analysis. Curr Opin Biotech 2000; 11: 54-61.
10. Karlsson RJ, SPR for molecular interaction analysis: a review of emerging application areas, Mol Recognit 2004; 17: 151-61.
11. Takeda H, Fukumoto A, Miura A, Goshima N, Nobuo N. Highthroughput kinase assay based on surface plasmon resonance suitable for native protein substrates. Anal Biochem 2006; 357: 262-71.
12. Wassaf D, Kuang G, Kopacz K, et al. High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays, Anal Biochem 2006; 15: 241-53.
13. Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, Myszka DG. Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal Biochem 2006; 358: 281-8.
14. Nahshol O, Bronner V, Notcovich A, Rubrecht L, Laune D, Bravman T. Parallel kinetic analysis and affinity determination of hundreds of monoclonal antibodies using the ProteOn XPR36. Anal Biochem 2008; 383: 52.
15. Bronner V, Nahshol O, Bravman T. Evaluating candidate lead compounds by rapid analysis of drug interactions with human serum albumin. Am Biotechnol Lab 2008; 26: 14-5.
16. Lausted C, Hu Z, Hood L. Label-free detection with surface plasmon resonance imaging. Methods Mol Biol 2011; 723: 321-33.
17. Tarazona MP, Saiz E. Combination of SEC/MALS experimental procedures and theoretical analysis for studying the solution properties of macromolecules. J Biochem Biophys Methods 2003; 56: 95-116.
18. Zagar E, Krzan A. SEC-MALS characterization of microbial polyhydroxyalkanoates. Biomacromolecules 2004; 5: 628-36.
19. Buchner J, Schmidt M, Fuchs M, et al. GroE facilitates refolding of citrate synthase by suppressing aggregation, Biochem 1991; 30: 1586-91.
20. Senisterra GA, Markin E, Yamazaki K, Hui R, Vedadi M, Awery DE. Screening for ligands using a generic and high-throughput light-scattering-based assay. J Biomol Screen 2008; 11: 940-8.
21. Capelle RG, Gurny R, Arvinte T. A high throughput protein formulation platform: case study of salmon calcitonin. Pharm Res 2009; 26: 118-28.
22. Semisotnov GV, Rodionova NA, Razgulyaev OI, Uversky VN, Gripas AF, Gilmanshin RI. Study of the "molten globule" intermediate state in protein folding by a hydrophobic fluorescent probe. Biopolimers 1991; 31: 119-28.
23. Hawe A, Friess W, Sutter M, Jiskoot W. Online fluorescent dye detection method for the characterization of IgG aggregation by size exclusion chromatography and asymmetrical flow field-flow fractionation. Anal Biochem 2008; 378: 115-22.
24. He F, Phan DH, Hogan S, et al. Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence. J Pharm Sci 2010; 99: 2598-608.
25. Mach H, Bhambhani A, Meyer BK, et al. The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations. J Pharm Sci 2011; 100: 1671-8.
26. Ludwig DB, Trotter JT, Gabrielson JP, Carpenter JF, Randolph TW. Flow cytometry: a promising technique for the study of silicone oil-induced particulate formation in protein formulations. Anal Biochem 2011; 15: 191-9.
27. Hawe A, Sutter M, Jiskoot W. Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 2008; 25: 1487-99.
28. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotech 2004; 22: 1302-6.
29. Maurer-Stroh S, Debulpaep M, Kuemmerer N, et al. Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat Methods 2010; 7: 237-42.
30. Conchillo-Solé O, de Groot NS, Avilés FX, Vendrell J, Daura X, Ventura S. AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides. BMC Bioinformatics 2007; 8: 65.
31. Trovato A, Seno F, Tosatto SC. The PASTA server for protein aggregation prediction. Protein Engineering, Design & Selection 2007; 20: 521-3.
32. Hamodrakas SJ. Protein aggregation and amyloid fibril formation prediction software from primary sequence: towards controlling the formation of bacterial inclusion bodies. FEBS J 2011; 278: 2428-35.
33. Wang X, Singh SK, Kumar S. Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Pharm Res 2010; 27: 1512-29.
34. Remmele RL, Gombotz WR. Differential scanning calorimetry: A practical tool for elucidating stability of liquid pharmaceuticals. Bio Pharm 2000; 13: 36-46.
35. Bruylants G, Wouters J, Michaux C. Differential scanning calorimetry in life sciences: thermodynamics, stability, molecular recognition and applications in drug design. Curr Med Chem 2005; 12: 2011-20.
36. Chang BS, Kendrick BS, Carpenter JF. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci 1996; 85: 1325-30.
37. Schiffer CA, Dötsch V. The role of protein-solvent interactions in protein unfolding. Curr Opin Biotechnol 1996; 7: 428-32.
38. Privalov GP, Privalov LP. Problems and perspectives in microcalorimetry of biological macromolecules. Methods Enzymol 2000; 323: 31-62.
39. Fon W, Axelrod BW, Roukes ML, Lee W. High-sensitivity microfluidic calorimeters for biological and chemical applications. PNAS 2009; 106: 18033-9.
40. Lerchner J, Wolf A, Wolf G, et al. A new micro-fluid chip calorimeter for biochemical applications. Thermochimica Acta 2006; 445: 144-50.
41. Vermeir S, Nicolai BM, Verboven P, et al. Microplate differential calorimetric biosensor for ascorbic acid analysis in food and pharmaceuticals. Anal Chem 2007; 79: 6119-27.
42. Wang L, Wang B, Lin Q. Demonstration of MEMS-Based Differential scanning calorimetry for determining thermodynamic properties of biomolecules. Sensors and Actuators B: Chemical 2008; 134: 953-8.
43. Asel CE, Springer BA, Lane P, et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 2001; 6: 429-40.
44. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 2010; 99: 1707-20.
45. Lo M-C, Aulabaugh A, Jin G, et al. Evaluation of fluorescencebased thermal shift assays for hit identification in drug discovery. Anal Biochem 2004; 332: 153-9.
46. Guido A, Malawski R, Hillig C, et al. Identifying protein construct variants with increased crystallization propensity - a case study. Protein Sci 2006; 15: 2718-28.
47. Ericsson UB, Hallberg BM, DeTitta GT, Dekker N, Nordlund P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal Biochem 2006; 357: 289-98.
48. Siedler M. Implementation of a platform approach for early biologics development. Am Pharm Rev 2011; 87: 87-91.
49. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. Downstream processing of monoclonal antibodies-application of platform approaches. J Chromatography B 2007; 848: 28-39.
50. Li Y, Mach H, Blue JT. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. J Pharm Sci 2011; 100: 2120-35.
51. Mahler HC, Müller R, Friess W, Delille A, Matheus S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 2005; 59: 407-17.
52. He F, Woods CE, Becker GW, Narhi LO, Razinkov VI. Highthroughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. J Pharm Sci 2011; 100: 5126-41.
53. Gopinath R, Naidu RAS. Pharmaceutical preformulation studies - current review. Int J Pharm & Biol Arch 2011; 2: 1391-140.
54. Zhao H, Graf O, Milovic N, et al. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J Pharm Sci 2010; 99: 2279-94.
55. Coles MM, Kessler HH. NMR-based screening technologies. Drug Disc Today 2003; 8: 803-10.
56. Marziali A, Willis TD, Davis RW. An arrayable flow-through microcentrifuge for high-throughput instrumentation. Proc Natl Acad Sci USA 1999; 96: 61-6.
57. Haidekker MA, Theodorakis EA. Molecular rotors - fluorescent biosensors for viscosity and flow. Org Biomol Chem 2007; 5: 1669-78.
58. He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI. High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem 2010; 399: 141-3.
59. He F, Woods CE, Trilisky E, et al. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. J Pharm Sci 2010; 100: 1330-40.
60. Saluja A, Kalonia DS. Application of ultrasonic shear rheometer to characterize rheological properties of high protein concentration solutions at microliter volume. J Pharm Sci 2005; 94: 1161-8.
61. Coffman J, Kramarczyk JF, Kelley BD. High-throughput screening of chromatographic separations: I. Method development and column modeling. Biotechnol Bioeng 2008, 100: 605-18.
62. Bensch M, Wierling PS, von Lieres E, Hubbuch J. High throughput screening of chromatographic phases for rapid process development. Chem Eng Technol 2005; 28: 1274-84.
63. Wierling PS, Bogumil R, Knieps-Grunhagen E, Hubbuch J. Highthroughput screening of packed-bed chromatography coupled with SELDI-TOF MS analysis: monoclonal antibodies versus host cell protein. Biotechnol Bioeng 2007; 98: 440-50.
64. Kamarczyk JF, Kelley BD, Coffman JL. High-throughput screening of chromatographic separrations: II. Hydrophobic interaction. Biotechnol Bioeng 2008; 100: 707-20.
65. Kelley BD, Switzer M, Bastek P, et al. High-throughput screening of chromatographic separations: IV. Ion-exchange. Biotechnol Bioeng 2008; 100: 950-63.
66. Wensel DL, Kramarczyk JF, Kelley BD, Coffman JL. Highthroughput screening of chromatographic separations: III. Monoclonal antibodies on ceramic hydroxyapatite. Biotechnol Bioeng 2008; 100: 839-54.
67. Capelle MA, Gurny R, Arvinte T. High throughput screening of protein formulation stability: practical considerations. Eur J Pharm Biopharm 2007; 65: 131-48.
68. Dasnoy S, Dezutter N, Lemoine D, Le Bras V, Préat V. Highthroughput screening of excipients intended to prevent antigen aggregation at air-liquid interface. Pharm Res 2011; 28: 1591-605.
69. Goldberg DS, Bishop SM, Shah AU, Sathish HA. Formulation development of therapeutic monoclonal antibodies using highthroughput fluorescence and static light scattering Techniques: role of conformational and colloidal stability. J Pharm Sci 2010; 100: 1306-15.
70. Pasch H, Kilz P. Fast liquid chromatography for high-throughput screening of polymers. Macromol Rapid Com 2003; 24: 104-8.
71. Hari SB, Lau H, Razinkov VI, Chen S, Latypov RF. Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. Biochem 2010; 49: 9328-38.
72. Schmidt R. Dynamic Light Scattering for Protein Characterization in: Encyclopedia of Analytical Chemistry, Wiley, 2010; pp. 31-45
73. Wyatt PJ. Light scattering and the absolute characterization of macromolecules. Analytica Cimica Acta 1993; 272: 1-40.
74. Feng BY, Shelat A, Doman TN, Guy RK, Shoichet BK. Highthroughput assays for promiscuous inhibitors. Nat Chem Biol 2005; 1: 146-8.
75. Chastek TQ, Beers KL, Amis EJ. Miniaturized dynamic light scattering instrumentation for use in microfluidic applications. Rev Sci Instr 2007; 78: 072201.
76. Wei Z, McEvoy M, Razinkov V, et al. Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity. J Virol Meth 2007; 144: 122-32.
77. McEvoy M, Razinkov V, Wei Z. Improved particle counting and size distribution determination of aggregated virus populations by asymmetric flow field-flow fractionation and multiangle light scattering techniques. Biotech Prog 2010; 27: 547-54.
78. Driscol DF, Etzler F, Barber TA, Nehne J, Niemann W, Bistrian BR. Physicochemical assessments of parenteral lipid emulsions: light obscuration versus laser diffraction; Int J Pharm 2001; 219: 21-37.
79. Etzler FM. Particle size analysis: a comparison of methods. Am Pharm Rev 2004; 7: 104-8.
80. Strehl R, Rombach-Riegraf V, Diez M, et al. Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: a novel multiparametric image filter for sub-visible particles in microflow imaging analysis. Pharm Res 2012; 29: 594-602.
81. Valet O, Lankers M, Adi H, Traini D, Young PM. The use of high throughput Raman microscopy for the concurrent size determination and chemical characterization of inhalation particles. Resp Drug Del 2010; 3: 763-8.
82. Zhao H, Graf O, Milovic N, et al. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J Pharm Sci 2010; 99: 2279-94.
83. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993; 10: 307-77.
84. Kayser V, Chennamsetty N, Voynov V, Helk B, Forrer K, Trout BL. Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation. J Pharm Sci 2011; 100: 2526-42.
85. Weiss WF 4th, Young TM, Roberts CJ. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci 2009; 98: 1246-77.
86. Saluja A, Fesinmeyer RM, Hogan S, Brems DN, Gokarn YR. Diffusion and sedimentation interaction parameters for measuring the second virial coefficient and their utility as predictors of protein aggregation. Biophys J 2010; 99: 2657-65.
87. Wales TE, Engen Jr. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev 2006; 25: 158-70.
88. Hambly D, Gross M. Microsecond time-scale hydroxyl radical profiling of solvent accessible protein residues. Compr Anal Chem 2008; 52: 151-77.
89. Ruponen M, Braun CS, Middaugh CR. Biophysical characterization of polymeric and liposomal gene delivery systems using empirical phase diagrams. J Pharm Sci 2006; 95: 2101-14.
90. Fan H, Li H, Zhang M, Middaugh CR. Effects of solutes on empirical phase diagrams of human fibroblast growth factor 1. J Pharm Sci 2006; 96: 1490-503.
91. Sellick CA, Hansen R, Jarvis RM, et al. Rapid monitoring of recombinant antibody production by mammalian cell cultures using fourier transform infrared spectroscopy and chemometrics. Biotechnol Bioeng 2010; 106: 432-42.
92. Landgrebe D, Haake C, Höpfner T, et al. Online infrared spectroscopy for bioprocess monitoring. Appl Microbiol Biotechnol 2010; 88: 11-22.
93. Anurag S. Rathore, Rohin Mhatre, Eds, Quality by Design for Biopharmaceuticals: Principles and Case Studies, Wiley-Blackwell (an imprint of John Wiley & Sons Ltd), 2009.
94. Anurag S, Winkle R, Winkle H. Quality by design for biopharmaceuticals. Nat Biotech 2009; 27: 26-34.
95. Rathore AS. A roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 2009; 27: 546-53.
96. US Food and Drug Administration. Guidance for industry. Pharmaceutical cGMPs for the 21st century - A risk based approach final report, MD, Rockville; 2004.
97. McKay B, Hoogenraad M, Damen EW, Smith AA. Advances in multivariate analysis in pharmaceutical process development. Curr Opin Drug Dis Dev 2003; 6: 966-77.
98. Box GE, Hunter JS, Hunter WG. Statistics for Experimenters: Design, Innovation, and Discovery, 2nd Edition, Wiley, 2005.
99. Sundaram J, Chung C, Hsu YH, Shay M, Sane SU. Design Space Development for Lyophilization Using DOE and Process Modeling: Develop a relevant design space without full factorial DoE. BioPharm International 2010; 23: 26-36.
100. Bower KM, Germansderfer A, Kerwin BA, Kleemann GR, Litowski Jr. Designed experiments with binary responses. J Pharm Sci 2011; 100: 5078-9.
101. Brandmaier S, Sahlin U, Tetko IV, Oberg T. PLS-Optimal: a stepwise D-Optimal design based on latent variables. J Chem Inf Model 2012; [Epub ahead of print].